ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

10. SEGMENTS (Tables)

6 Months Ended

Jun. 30, 2019

Three Months Ended June 30, 2019
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	4,002,445		$	2,522,788		$	35,709		$	6,560,942

Cost of product revenue		8,170,381			2,320,855			—			10,491,236

Loss from operations		(8,671,783	)		(392,181	)		(2,274,710	)		(11,338,674	)

Interest and other expense, net		(246,603	)		(59	)		(1,626,536	)		(1,873,198	)

Net loss		(8,918,386	)		(392,240	)		(3,901,246	)		(13,211,872	)

Depreciation and amortization		688,848			113,958			3,287			806,093

Total assets		67,236,416			3,835,999			72,201,705			143,274,120

Three Months Ended June 30, 2018
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	2,144,724		$	2,476,117		$	35,709		$	4,656,550

Cost of product revenue		7,965,681			1,679,981			—			9,645,662

Loss from operations		(9,918,243	)		(941,993	)		(2,557,145	)		(13,417,381	)

Interest and other expense, net		(237,161	)		(436	)		(1,092,853	)		(1,330,450	)

Net loss		(10,155,404	)		(942,429	)		(3,649,998	)		(14,747,831	)

Depreciation and amortization		639,300			200,598			6,001			845,899

Total assets		54,297,915			5,438,645			58,015,432			117,751,992

Six Months Ended June 30, 2019
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	5,346,428		$	4,671,686		$	71,417		$	10,089,531

Cost of product revenue		16,110,727			3,785,688			—			19,896,415

Loss from operations		(19,292,591	)		(362,601	)		(4,891,898	)		(24,547,090	)

Interest and other (expense) income, net		(416,216	)		13,560			(2,895,007	)		(3,297,663	)

Gain on transfer of plasma center assets		—			11,527,421			—			11,527,421

Loss on extinguishment of debt		—			—			(9,962,495	)		(9,962,495	)

Net (loss) income		(19,708,807	)		11,178,380			(17,749,400	)		(26,279,827	)

Depreciation and amortization		1,376,240			228,199			6,983			1,611,422

Capital expenditures		224,440			21,235			—			245,675

Six Months Ended June 30, 2018
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	3,810,967		$	4,816,172		$	71,417		$	8,698,556

Cost of product revenue		18,663,323			3,225,087			—			21,888,410

Loss from operations		(22,642,709	)		(1,980,817	)		(5,326,358	)		(29,949,884	)

Interest and other expense, net		(477,214	)		(871	)		(2,142,004	)		(2,620,089	)

Net loss		(23,119,923	)		(1,981,688	)		(7,468,362	)		(32,569,973	)

Depreciation and amortization		1,271,131			389,512			14,796			1,675,439

Capital expenditures		591,665			454,710			—			1,046,375